Catalent, Inc.
DelistedCIK 1596783fmd_0HHP6AT66DY9WDYWP1Q6R8C1EVManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2011 to Dec 31, 2024, 51 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1,831 | 1,848 | 2,075 | 2,463 | 2,518 | 3,094 | 3,998 | 4,802 | 4,263 | 4,381 |
| Cost of revenue | 1,216 | 1,261 | 1,421 | 1,711 | 1,713 | 2,111 | 2,646 | 3,188 | 3,223 | 3,428 |
| Net interest income | (105) | (89) | (90) | (111) | (111) | (126) | (110) | (123) | (186) | (254) |
| Gross profit | 615 | 588 | 655 | 753 | 805 | 983 | 1,352 | 1,614 | 1,040 | 953 |
| Realized investment gains (losses) | – | 4 | – | – | – | – | – | – | – | – |
| Research and development | – | – | – | – | 19 | 21 | 21 | 23 | 18 | 17 |
| Selling, general and administrative | 337 | 358 | 403 | 465 | 512 | 577 | 687 | 844 | 829 | 935 |
| Operating income | 260 | 218 | 234 | 269 | 274 | 394 | 828 | 730 | (163) | (749) |
| Other non-operating income (expense) | (42) | 16 | (9) | (6) | (3) | (8) | (3) | 28 | 7 | 24 |
| Income before taxes | 113 | 145 | 136 | 152 | 160 | 260 | 715 | 579 | (342) | (1,027) |
| Income tax expense | (98) | 34 | 26 | 68 | 23 | 39 | 130 | 80 | (86) | 16 |
| Net income from continuing operations | 210 | 111 | 110 | 84 | 137 | 221 | 585 | 499 | (256) | (1,043) |
| Net income | 212 | 112 | 110 | 84 | 137 | 221 | 585 | 499 | (256) | (1,043) |
| Net income to common shareholders | – | – | 110 | 84 | 132 | 173 | 529 | 483 | (256) | (1,043) |